neoadjuvant anti-PD-1
SCE2401
Phase 2 small_molecule active
Quick answer
neoadjuvant anti-PD-1 for Esophageal Cancer is a Phase 2 program (small_molecule) at Shanghai Chest Hospital with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Shanghai Chest Hospital
- Indication
- Esophageal Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active